NCT00314145View on ClinicalTrials.gov

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

PHASE3CompletedINTERVENTIONAL
Enrollment

820

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

November 30, 2006

Conditions
Japanese Encephalitis
Interventions
BIOLOGICAL

ChimeriVax™-JE

0.5 mL, Subcutaneous (ChimeriVax™-JE); 1.0 mL, (Saline)

BIOLOGICAL

JE-VAX®

0.5 mL, Subcutaneous (JE-Vax®); 1.0 mL, (Saline)

Trial Locations (10)

59802

Missoula

60610

Chicago

66216

Shawnee Mission

75231

Dallas

98403

Tacoma

Unknown

Adelaide

Melbourne

New South Wales

Queensland

Victoria

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY